SMET 12
Alternative Names: SMET-12Latest Information Update: 22 Jan 2024
At a glance
- Originator Zhejiang Shimai Pharmaceutical
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 17 Jan 2024 Fujian Cancer Hospital plans an early phase I trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, First-line therapy, Second-line therapy or greater) in China (IV) (NCT06208033)
- 13 Jun 2022 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (IV) before June 2022 (Zhejiang Shimai Pharmaceutical pipeline, June 2022)
- 13 Jun 2022 Zhejiang Shimai Pharmaceutical plans to submit NDA in Solid tumours in China in 2024 (Zhejiang Shimai Pharmaceutical pipeline, June 2022)